| Date | Form | Description | Docs | XBRL | Pages |
| 05/26/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
32 |
| 05/17/17 | 8-K | Current report filing |
|
30 | |
| 05/15/17 | 424B2 | Prospectus filed pursuant to Rule 424(b)(2) |
|
51 | |
| 05/11/17 | 424B2 | Prospectus filed pursuant to Rule 424(b)(2) |
|
51 | |
| 04/13/17 | 8-K | Current report filing |
|
3 | |
| 04/10/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 04/06/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 04/05/17 | 8-K | Current report filing |
|
4 | |
| 04/04/17 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 04/03/17 | UPLOAD | SEC-generated letter |
|
1 |
Latest News & Events
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Read More...Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting
Read More...Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
Read More...